ArticleGlobalization and health2017
Obstacles and opportunities in Chinese pharmaceutical innovation.
Article in Globalization and health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Visual analysis of quality management in Chinese drug clinical trials based on CiteSpace and COOC.Frontiers in medicine · 2025Pooled it
- Innovative Drugs Approved in China After Registration Classification Reform: Current Status, Disparities, and Challenges.Clinical pharmacology and therapeutics · 2026Article
- Decolonizing global health: Africa's pursuit of pharmaceutical sovereignty.BMC health services research · 2025Review
- Regulatory efforts to address the access gap for foreign new drugs in China: the priority review program and related policies.Global health research and policy · 2025Article
- Attention-based deep learning for accurate cell image analysis.Scientific reports · 2025Article
- Reforming the innovation system to deliver affordable medicines: a conceptual framework of pharmaceutical innovation as a complex adaptive system (forest) and theory of change.Journal of pharmaceutical policy and practice · 2025Article
- A Patent Analysis on Nano Drug Delivery Systems.Recent patents on nanotechnology · 2025Review
- Comprehensive evaluation of the development of traditional Chinese medicine industry in Shaanxi province based on PMC index model.Frontiers in public health · 2025Article
- Bridging the new drug access gap between China and the United States and its related policies.Frontiers in pharmacology · 2023Article
- The reimbursement decision speed for oncology new drugs in China and its determinant factors.Frontiers in public health · 2023Article
- Future health spending forecast in leading emerging BRICS markets in 2030: health policy implications.Health research policy and systems · 2022Article
- Measure on innovation efficiency of China's pharmaceutical manufacturing industry.Frontiers in public health · 2022Article
- Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Review
- Research capacity of global health institutions in China: a gap analysis focusing on their collaboration with other low-income and middle-income countries.BMJ global health · 2021Article
- Will Innovation of Pharmaceutical Manufacturing Improve Perceived Health?Frontiers in public health · 2021Article
- R&D Investments, Debt Capital, and Ownership Concentration: A Three-Way Interaction and Lag Effects on Firm Performance in China's Pharmaceutical Industry.Frontiers in public health · 2021Article
- Policy Analysis Of Iranian Pharmaceutical Sector; A Qualitative Study.Risk management and healthcare policy · 2019Article
- Gap analysis for drug development policy-making: An attempt to close the gap between policy and its implementation.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobal healthcare innovation networks nowadays have expanded beyond developed countries with many developing countries joining the force and becoming important players. China, in particular, has seen a significant increase in the number of innovative firms and research organizations stepping up to the global network in recent years. Nevertheless, the intense Research and Development input has not brought about the expectable output. While China is ascending at a great speed to a leading position worldwide in terms of Research and Development investment, scientific publications and patents, the innovation capabilities in the pharmaceutical sector remain weak. DISCUSSION: This study discusses the challenges and opportunities for pharmaceutical innovation in China. One hand, academic, industrial, institutional and financial constraints were found to be the major and inevitable barriers hindering the development of drug innovation. On the other hand, unique advantages had been observed which included growing pharmaceutical market, Research and Development funding, distinctive source, and international cooperation. The most important thing for China's pharmaceutical sector to leap forward is to break though innovation barriers and integrate own advantages into global value-chain of healthcare product development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.